Results 111 to 120 of about 12,381 (205)

Radioimmunotherapy combating biofilm-associated infection in vitro

Frontiers in Medicine
BackgroundAddressing prosthetic joint infections poses a significant challenge within orthopedic surgery, marked by elevated morbidity and mortality rates. The presence of biofilms and infections attributed to Staphylococcus aureus (S.
Zijian Ye, Berend van der Wildt, F. Ruben H. A. Nurmohamed, J. Fred F. Hooning van Duyvenbode, Jos van Strijp, H. Charles Vogely, Marnix G. E. H. Lam, Ekaterina Dadachova, Harrie Weinans, Harrie Weinans, Bart C. H. van der Wal, Alex J. Poot   +11 more
doaj   +1 more source

Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using 149Tb-rituximab [PDF]

, 2018
This study demonstrates high-efficiency sterilisation of single cancer cells in a SCID mouse model of leukaemia using rituximab, a monoclonal antibody that targets CD20, labelled with terbium-149, an alpha-emitting radionuclide.
Beyer, G.-J, Buchegger, F., Hartley, O., Künzi, G., Miederer, M., Senekowitsch-Schmidtke, R., Soloviev, D., Vranješ-Đurić, S., Čomor, J.   +8 more
core  

Repeated injections of 131I-rituximab show patient-specific stable biodistribution and tissue kinetics [PDF]

, 2018
Purpose: It is generally assumed that the biodistribution and pharmacokinetics of radiolabelled antibodies remain similar between dosimetric and therapeutic injections in radioimmunotherapy.
Antonescu, Cristian, Bischof Delaloye, Angelika, Buchegger, Franz, Grannavel, Carine, Ketterer, Nicolas, Kosinski, Marek, Kovacsovics, Tibor, Monnin, Pascal, Schaffland, Andreas, Verdun, Francis   +9 more
core  

Targeting Cancer Stem Cells with Radioimmunotherapy: The Case of the Ovarian Cancer Stemness-Associated Biomarker L1CAM

International Journal of Translational Medicine
Cancer stem cells (CSCs) are a dynamic population of tumor cells characterized by long-term self-renewal, high tumorigenicity, resistance to conventional therapies such as radio- and chemotherapy, and capacity to recapitulate the tumor heterogeneity ...
Tihomir Zh. Todorov, Roger Schibli, Martin Béhé, Jürgen Grünberg   +3 more
doaj   +1 more source

Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin’s lymphoma

Exploration of Targeted Anti-tumor Therapy
Radioimmunotherapy (RIT) is a therapy that combines a radioactive nucleotide with a monoclonal antibody (mAb). RIT enhances the therapeutic effect of mAb and reduces toxicity compared with conventional treatment.
Hiroki Goto, Yoshioki Shiraishi, Seiji Okada   +2 more
doaj   +1 more source

Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u27s lymphoma and mild thrombocytopenia [PDF]

, 2004
Bartlett, Nancy, Gordon, Leo, Molina, Arturo, Murray, James, Schilder, Russell, Spies, Stewart, Wang, Hua, White, Christine, Wiseman, Gregory, Witzig, Thomas   +9 more
core   +2 more sources

Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies [PDF]

, 2006
R. O. Dillman, R.O. Dillman, R.O. Dillman, R.O. Dillman, P. McLaughlin, T.E. Witzig, P. Colombat, J.D. Hainsworth, M. Ghielmini, M.S. Czuczman, M.S. Czuczman, J.M. Vose, P. Feugier, T.M. Habermann, M. Pfreundschuh, R. Marcus, R. Forstpointner, L.H. Sehn, R.I. Fisher, R.O. Dillman, R.O. Dillman, B.D. Cheson, J.A. Siegel, V.L. Gates, F.J. Rutar, H.N. Wagner Jr, G.A. Wiseman, W.D. Erwin, G.A. Wiseman, G. Wiseman, M.S. Kaminski, T.E. Witzig, R.O. Dillman, J.M. Vose, A.J. Davies, T.E. Witzig, M.S. Kaminski, A.D. Zelenetz, N.L. Bartlett, J.P. Leonard, T.A. Davis, T.E. Witzig, S.J. Horning, L.I. Gordon, G.A. Wiseman, R.I. Fisher, I.W. Flinn, M.S. Kaminski, M.S. Kaminski, J.W. Sweetenham, C.E. Emmanouilides, S.A. Gregory, M.S. Kaminski, S.M. Ansell, R.J. Schilder, F. Saleh, A. Dosik, O.W. Press, B. Link, J.P. Leonard, D.L. Shipley, S.A. Jacobs, J.M. Vose, O.W. Press, O.W. Press, S.Y. Liu, J.G. Rajendran, O.W. Press, A.K. Gopal, J.N. Winter, A. Nademanee, J. Joyce, F. Morschhauser, A.D. Zelenetz, Y. Oki, T.E. Witzig, G.A. Wiseman, R. Schilder, M. Czuczman, J.M. Bennett, L.E. Holm   +80 more
core   +1 more source

"Boom-Boom" radioimmunotherapy of lymphomas: Are two magic bullets better than one? [PDF]

, 2016
Cicone F. Prior J.O. Scopinaro F.,
core   +1 more source

PD‐1 Blockade Enhances Therapeutic Effects of Anti‐CEA 177Lu‐DOTA‐M5A in Colorectal Cancer CEA‐Transgenic Mice

MedComm – Future Medicine
Tumor‐targeted radioimmunotherapy (RIT) has the dual capability of delivering ionizing radiation to cancer cells while modulating the tumor microenvironment (TME) to enhance immune responses.
Tabassom Mohajershojai, Emil Bengtsson, Ingrid Vallin, Douglas Spangler, Marit Melssen, Paul J. Yazaki, Marika Nestor   +6 more
doaj   +1 more source

Radioimmunotherapy [PDF]

, 2020
openaire   +1 more source